

Reported Perioperative Practices for Candida auris Colonization among Surgical and Transplant Patients

Hassneiah D¹, Pepe DE¹, Beekmann SE², Polgreen PM², Mehrotra P¹, Lee MSL¹.

(1) Division of Infectious Diseases and Division of Infection Control/Hospital Epidemiology, Beth Israel Deaconess Medical Center, Boston, USA (2) Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, USA

CONTACT INFORMATION:

Dana Hassneiah, MD, MPH
Division of Infectious Diseases,
BIDMC, 110 Francis St, Boston, MA
02215, USA

Phone: (305) 812-6821

Email:

dhassnei@bidmc.harvard.edu

BACKGROUND

- Candida auris is an emerging multidrug-resistant pathogen that can cause healthcare-associated infections and outbreaks.
- Despite its increasing prevalence in healthcare settings, there is limited data or guidance related to perioperative infection prevention in patients colonized with *C. auris*.
- CDC guidelines do not address perioperative screening or management of *C. auris* in surgical patients, including solid organ transplant donors and recipients.
- This study examines the reported experiences and approaches infectious diseases professionals take in managing *C. auris* colonization perioperatively.

METHODS

- Emerging Infections Network (EIN) Quick Queries are a unique tool that utilize focused rapidly-deployable polls to ascertain members' opinions/approaches to emerging infectious diseases with limited data, allowing for hypothesis generation or identifying areas of need.
- An online "Quick Query" poll was distributed to members of the EIN.
- Our poll included 6 questions assessing perioperative prevention of *C. auris* infection.
- Descriptive analysis was used to evaluate responses.

Key Points:

- Only 18% of respondents reported presence of *C. auris* perioperative management institutional guidelines.
- 19% of poll respondents encountered postoperative invasive *C. auris* infections in previously colonized surgical and transplant patients.




Figure 3: Respondents reporting routine perioperative antifungal prophylaxis for *C. auris* colonized patients

Yes No

ACKNOWLEDGEMENT

The authors gratefully acknowledge the members of the EIN who responded to the "Quick Query" poll and contributed their insights to this study.

RESULTS

- 84 EIN members completed the poll, representing 29 U.S. states and 3 other countries/territories. California accounted for the largest share of responses (17%), followed by Massachusetts (7%), and Florida (6%).
- Institutional protocols for *C. auris* prevention/management in surgical patients were reported by 18% (15/84) respondents; 17% (14/84) respondents reported having a general surgical guideline and only one respondent reported having a transplant-specific guideline (Figure 1).
- Preoperative screening for *C. auris* was reported by 8% (7/84) of respondents, predominantly from California (5/7) (Figure 2).
- Among the 44 respondents who encountered colonized surgical patients, only 9% (4/44) used antifungal prophylaxis (Figure 3), with micafungin as the preferred agent.
- *C. auris* colonization in transplant recipients prior to transplantation was reported by 13% of respondents (11/84), while only 2% (2/84) reported encounters involving transplants from colonized donors.
- 15% of respondents (13/84) encountered postoperative invasive *C. auris* infections in colonized surgical patients and 4% (3/84) in colonized transplant recipients. 3 additional cases were described among transplant recipients without known donor or recipient colonization pre-transplant.

CONCLUSION

- The survey highlights the lack of institutional guidelines for *C.* auris prevention in perioperative settings, including among solid-organ transplant patients.
- Postoperative *C. auris* infections are being encountered, although uncommon, underscoring the need for further research and standardized guidelines to address perioperative prevention of this emerging pathogen.